Nuvectis Pharma, Inc.

NasdaqCM:NVCT Stock Report

Market Cap: US$218.4m

Nuvectis Pharma Management

Management criteria checks 4/4

Nuvectis Pharma's CEO is Ron Bentsur, appointed in Jul 2020, has a tenure of 4.83 years. total yearly compensation is $1.16M, comprised of 54.8% salary and 45.2% bonuses, including company stock and options. directly owns 14.14% of the company’s shares, worth $30.87M. The average tenure of the management team and the board of directors is 4.8 years and 3.7 years respectively.

Key information

Ron Bentsur

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage54.79%
CEO tenure4.8yrs
CEO ownership14.1%
Management average tenure4.8yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Oct 20
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

Jun 26
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

Jan 06
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Oct 03
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Jan 31
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Nuvectis Pharma forms scientific advisory board for research and development of drugs

Sep 28

Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04

Aug 05

Nuvectis Pharma declines 13%, announces $15.9M private placement

Jul 27

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

May 04
We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

CEO Compensation Analysis

How has Ron Bentsur's remuneration changed compared to Nuvectis Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$20m

Dec 31 2024US$1mUS$634k

-US$19m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023US$3mUS$615k

-US$22m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$2mUS$420k

-US$19m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$384kn/a

-US$13m

Compensation vs Market: Ron's total compensation ($USD1.16M) is about average for companies of similar size in the US market ($USD1.60M).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.

CEO

Ron Bentsur (58 yo)

4.8yrs

Tenure

US$1,157,639

Compensation

Mr. Ron Bentsur, M.B.A. is a Co-Founder of Nuvectis Pharma, Inc. on July 27, 2020 and serves as its Chairman, Chief Executive Officer and President since 2020. He has been Advisor of UroGen Pharma Ltd. sin...

Leadership Team

NamePositionTenureCompensationOwnership
Ron Bentsur
Co-Founder4.8yrsUS$1.16m14.14%
$ 30.9m
Enrique Poradosu
Co-Founder4.8yrsUS$1.81m6.6%
$ 14.4m
Shay Shemesh
Co-Founder4.8yrsUS$1.81m6.54%
$ 14.3m
Michael Carson
Vice President of Finance3.2yrsno data0.59%
$ 1.3m

4.8yrs

Average Tenure

52.5yo

Average Age

Experienced Management: NVCT's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ron Bentsur
Co-Founder5.3yrsUS$1.16m14.14%
$ 30.9m
James Oliviero
Independent Director3.8yrsUS$559.07k0.24%
$ 534.3k
Gordon Mills
Member of Scientific Advisory Board2.7yrsno datano data
Matthew Kaplan
Independent Director3.7yrsUS$549.07k0.35%
$ 774.0k
Paul Workman
Member of Scientific Advisory Board2.7yrsno datano data
Kenneth Hoberman
Independent Director3.8yrsUS$559.07k0.44%
$ 953.0k
Shannon Westin
Member of Scientific Advisory Board2.7yrsno datano data

3.7yrs

Average Tenure

57yo

Average Age

Experienced Board: NVCT's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/15 20:13
End of Day Share Price 2025/05/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvectis Pharma, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Aydin HuseynovLadenburg Thalmann & Company
I-Eh JenLaidlaw & Company (UK) Ltd